MIRUM PHARMACEUTICALS INC

Mirum Pharma’s insider buying signals confidence ahead of LIVMARLI’s sNDA, suggesting a potential valuation lift despite regulatory risks.

Mirum Pharmaceuticals CEO Christopher Peetz’s recent bulk purchase signals a long‑term bet on the company’s liver‑disease pipeline, hinting at future catalysts.

Mirum Pharmaceuticals insider activity shows senior leadership confidence amid price consolidation—key insights for investors on the future of cholestatic liver‑disease treatments.

Mirum Pharmaceuticals insider buy signals confidence in future liver‑disease pipeline, tech edge, and reimbursement prospects—why investors should watch its next milestones.